CHINA Beijing to conduct COVID-19 antibody survey to optimize measures

CHINA

Beijing to conduct COVID-19 antibody survey to optimize measures

CGTN

14:12, February 01, 2023

Tourists visit the Palace Museum, or the Forbidden City, in Beijing, capital of China, January 31, 2023. /CFP

Chinese capital Beijing will carry out a survey to measure COVID-19 antibody levels in its population to help assess the current situation and better prepare for future infections, said a local health official on Tuesday.

Wang Quanyi, deputy director of the Beijing Center for Disease Prevention and Control, said during an interview with Beijing News that the city plans to conduct serological tests, which target antibodies triggered by a previous infection, on about 5,000 residents from February to March.

The survey participants will also fill out a questionnaire on their nucleic acid and antibody testing results, vaccination status and the course of their infection and treatment.

Survey findings will be used to optimize the allocation of anti-virus resources as well as future policies, Wang added.

Wang said Beijing has passed the peak of the latest COVID-19 wave and is nearing its end, and the current dominant strains are BF.7 and BA.5.2.

With immunity gained from recent infections, the possibility of seeing another wave in at least three months is very low, Wang said, adding that the increase in return trips to Beijing during the Spring Festival travel rush will not cause trouble as the nationwide epidemic is also in decline.

While Beijing has established temporary immunity among its population and is unlikely to experience a fresh wave in the short term, Wang suggested people aged 80 and above get vaccinated soon.

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue